Azacitidine compared to conventional chemotherapy in consolidation of elderly patients (> 65 years) with AML in first complete remission

Trial Profile

Azacitidine compared to conventional chemotherapy in consolidation of elderly patients (> 65 years) with AML in first complete remission

Discontinued
Phase of Trial: Phase II

Latest Information Update: 13 Apr 2016

At a glance

  • Drugs Azacitidine (Primary) ; Cytarabine; Daunorubicin
  • Indications Acute myeloid leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Apr 2016 Status changed from completed to discontinued, as reported by European Clinical Trials Database record.
    • 04 Jul 2015 Status changed from recruiting to completed, as reported by European Clinical Trials Database record.
    • 19 Feb 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top